Dyslipidemia

Intensive LDL-C lowering reduces mortality in patients with higher baseline LDL-C

More intensive compared with less intensive LDL-C lowering therapy was associated with a greater risk reduction for total and cardiovascular mortality in trials of patients with higher baseline LDL-C levels.

FDA Committee in Favor of Waylivra for Rare Metabolic Lipid Disorder

FDA Committee in Favor of Waylivra for Rare Metabolic Lipid Disorder

By

Antisense technology refers to the use of synthetic nucleic acid sequences to interrupt specific protein production by targeting the corresponding messenger RNA that encodes that protein.

Higher LDL-C Levels Derive Most Benefit From More Intensive Therapy

Higher LDL-C Levels Derive Most Benefit From More Intensive Therapy

By

Patients with higher low-density lipoprotein cholesterol levels experienced the greatest reductions in all-cause and cardiovascular mortality from intensive therapy.

Breathing New Life Into COPD and Asthma Therapy With Statins

Breathing New Life Into COPD and Asthma Therapy With Statins

Statins have anti-inflammatory and anti-oxidative effects, which could reduce exacerbations of both asthma and chronic obstructive pulmonary disease.

Outcomes-Based Pricing Does Not Cut Costs of PCSK9 Inhibitors

Outcomes-Based Pricing Does Not Cut Costs of PCSK9 Inhibitors

Incremental cost-effectiveness ratio for PCSK9 inhibitor improved marginally in 3 refund scenarios.

Only Half of Adults With Familial Hypercholesterolemia on Statins

Only Half of Adults With Familial Hypercholesterolemia on Statins

Only 30.3 percent of patients with definite or probable FH on statins take a high-intensity statin.

Metformin Use Linked to Reduced Risk for Statin-Associated Muscle Pain

Metformin Use Linked to Reduced Risk for Statin-Associated Muscle Pain

By

Statin-associated muscle pain can hinder medication adherence which could potentially lead to an increased risk of cardiovascular events.

Statins Do Not Affect Influenza Risk Following Vaccination

Statins Do Not Affect Influenza Risk Following Vaccination

By

Statin medications taken around the time of influenza vaccination do not appear to affect the risk for influenza in older patients.

LDL-C Levels With Intensive Treatment for Autosomal Recessive Hypercholesterolemia

LDL-C Levels With Intensive Treatment for Autosomal Recessive Hypercholesterolemia

For patients with autosomal recessive hypercholesterolemia, low-density lipoprotein cholesterol levels remain high despite intensive treatment.

Accuracy of New Estimation Method for Low-Density Lipoprotein Cholesterol Levels

Accuracy of New Estimation Method for Low-Density Lipoprotein Cholesterol Levels

By

An adjustable triglyceride/very low-density lipoprotein cholesterol ratio based on triglycerides and non-high-density lipoprotein cholesterol is more accurate than the fixed Friedewald estimation.

CVD, Mortality May Be Affected by Visit-to-Visit Fasting Plasma Glucose Variability

CVD, Mortality May Be Affected by Visit-to-Visit Fasting Plasma Glucose Variability

By

Patients with visit-to-visit variability of fasting plasma glucose may have a higher risk of developing cardiovascular disease and all-cause mortality.

FDA Approves PCSK9 Inhibitor for Stroke, MI Prevention

FDA Approves PCSK9 Inhibitor for Stroke, MI Prevention

By

The FDA has approved evolocumab for the prevention of heart attacks.

Almonds With or Without Dark Chocolate May Improve Lipid Profiles in Controlled Feeding Conditions

Almonds With or Without Dark Chocolate May Improve Lipid Profiles in Controlled Feeding Conditions

Lipid profiles of overweight people can be improved by eating raw almonds, dark chocolate, and cocoa.

PCSK9 Inhibitor Resistance May Be Identified by Plasma PCSK9

PCSK9 Inhibitor Resistance May Be Identified by Plasma PCSK9

PCSK9 may help assess apparent resistance to PCSK9 inhibitors.

Lower Risk for Adverse CV Outcomes With Evolocumab, With/Without Diabetes

Lower Risk for Adverse CV Outcomes With Evolocumab, With/Without Diabetes

By

Evolocumab may decrease the risk for adverse cardiovascular events in patients with and without diabetes.

PCSK9 Inhibitor Approved in Less Than Half of Insurance Claims

PCSK9 Inhibitor Approved in Less Than Half of Insurance Claims

Rates of approval for a PCSK9 inhibitor treatment are low overall.

PCSK9 Inhibitor Does Not Affect Cognitive Function

PCSK9 Inhibitor Does Not Affect Cognitive Function

By

Evolocumab is not associated with adverse cognitive effects even when low low-density lipoprotein cholesterol levels have been achieved.

Dyslipidemia in Children With HIV After Starting Antiretroviral Therapy

Dyslipidemia in Children With HIV After Starting Antiretroviral Therapy

By

Serum lipid profile changes were shown to occur within the first year of initiating antiretroviral therapy in children.

Coexisting COPD and Elevated CVD Risk May Benefit From Statins

Coexisting COPD and Elevated CVD Risk May Benefit From Statins

By

Researchers find statins could be a potential treatment option in COPD.

Less Than Half of Patients Prescribed PCSK9 Inhibitors Receive Approval

Less Than Half of Patients Prescribed PCSK9 Inhibitors Receive Approval

Less than half of patients prescribed PCSK9 inhibitors receive approval, and only about 30% ever receive therapy.

FDA Approves Pitavastatin for Mixed Dyslipidemia and Hyperlipidemia

FDA Approves Pitavastatin for Mixed Dyslipidemia and Hyperlipidemia

By

The FDA has approved a new pitavastatin for the treatment of primary hyperlipidemia or mixed dyslipidemia.

Anacetrapib Reduces Major Coronary Events When Added to Intensive Statin Therapy

Anacetrapib Reduces Major Coronary Events When Added to Intensive Statin Therapy

Lower incidence of major coronary events for patients with atherosclerotic vascular disease receiving intensive statins is linked with use of anacetrapib.

Cardiovascular Event Risk Better Predicted by ApoB vs LDL Cholesterol Level

Cardiovascular Event Risk Better Predicted by ApoB vs LDL Cholesterol Level

Clinical benefit of reduced low-density lipoprotein cholesterol (LDL-C) levels may depend on the corresponding reduction in apolipoprotein B (apoB)-containing lipoprotein particles.

Anti-Tumor Necrosis Factor Drug Improves CV Health in Psoriatic Arthritis

Anti-Tumor Necrosis Factor Drug Improves CV Health in Psoriatic Arthritis

By

Cardiovascular health in psoriatic arthritis improves with anti-tumor necrosis factor drug etanercept.

PCSK9 Inhibitor Evolocumab Continues to Lack Cost-Effectiveness

PCSK9 Inhibitor Evolocumab Continues to Lack Cost-Effectiveness

Findings for addition of evolocumab to standard tx in atherosclerotic cardiovascular disease

Antidepressant Mislabeled as Cholesterol Drug: Recall

Antidepressant Mislabeled as Cholesterol Drug: Recall

By

International Laboratories, LLC has issued a recall for one lot of Pravastatin Sodium Tablets 40mg due to mislabeling.

Evolocumab Added to Statin Therapy Does Not Affect Cognition

Evolocumab Added to Statin Therapy Does Not Affect Cognition

There is no significant difference in cognitive function for patients treated with evolocumab or placebo added to statin therapy.

Marked Variations in Statin Use in Nursing Home Residents

Marked Variations in Statin Use in Nursing Home Residents

Statin prescribing trends vary among nursing home residents with significant variation of prescribing across physicians.

Multiple Cardiometabolic Comorbidities Prevalent in Psoriasis

Multiple Cardiometabolic Comorbidities Prevalent in Psoriasis

By

Patients with psoriasis have high rates of cardiometabolic comorbidities.

Noncalcified, High-Risk Coronary Plaque Burden Increased With Psoriasis

Noncalcified, High-Risk Coronary Plaque Burden Increased With Psoriasis

By

Individuals with psoriasis have a greater risk for noncalcified coronary plaque burden compared with healthy individuals and patients with hyperlipidemia.

Sign Up for Free e-Newsletters